Jean-Pierre Bizzari, MD

CAB Member

Jean-Pierre Bizzari, MD is a world-renowned oncology expert who served as Executive Vice President, Group Head, and Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. Before that, Dr. Bizzari was Head of Clinical Development at RPR-Aventis and Sanofi. Drugs he has helped develop include Taxotere, CPT-11, oxaliplatin, Abraxane, Revlimid, and Vidaza.

He is an active board member of various biotech companies and a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and the European Organisation for Research and Treatment of Cancer (EORTC).